183 related articles for article (PubMed ID: 33522595)
21. Bioreactor productivity and media cost comparison for different intensified cell culture processes.
Xu S; Gavin J; Jiang R; Chen H
Biotechnol Prog; 2017 Jul; 33(4):867-878. PubMed ID: 27977910
[TBL] [Abstract][Full Text] [Related]
22. Process design of a fully integrated continuous biopharmaceutical process using economic and ecological impact assessment.
Ding C; Ardeshna H; Gillespie C; Ierapetritou M
Biotechnol Bioeng; 2022 Dec; 119(12):3567-3583. PubMed ID: 36109341
[TBL] [Abstract][Full Text] [Related]
23. Orbitally Shaken Single-Use Bioreactor for Animal Cell Cultivation: Fed-Batch and Perfusion Mode.
Bürgin T; Coronel J; Hagens G; Keebler MV; Genzel Y; Reichl U; Anderlei T
Methods Mol Biol; 2020; 2095():105-123. PubMed ID: 31858465
[TBL] [Abstract][Full Text] [Related]
24. The Current Scientific and Regulatory Landscape in Advancing Integrated Continuous Biopharmaceutical Manufacturing.
Fisher AC; Kamga MH; Agarabi C; Brorson K; Lee SL; Yoon S
Trends Biotechnol; 2019 Mar; 37(3):253-267. PubMed ID: 30241924
[TBL] [Abstract][Full Text] [Related]
25. Data mining for rapid prediction of facility fit and debottlenecking of biomanufacturing facilities.
Yang Y; Farid SS; Thornhill NF
J Biotechnol; 2014 Jun; 179():17-25. PubMed ID: 24637375
[TBL] [Abstract][Full Text] [Related]
26. The business impact of an integrated continuous biomanufacturing platform for recombinant protein production.
Walther J; Godawat R; Hwang C; Abe Y; Sinclair A; Konstantinov K
J Biotechnol; 2015 Nov; 213():3-12. PubMed ID: 26014522
[TBL] [Abstract][Full Text] [Related]
27. Design and operation of a continuous integrated monoclonal antibody production process.
Steinebach F; Ulmer N; Wolf M; Decker L; Schneider V; Wälchli R; Karst D; Souquet J; Morbidelli M
Biotechnol Prog; 2017 Sep; 33(5):1303-1313. PubMed ID: 28691347
[TBL] [Abstract][Full Text] [Related]
28. Process intensification to produce a difficult-to-express therapeutic enzyme by high cell density perfusion or enhanced fed-batch.
Särnlund S; Jiang Y; Chotteau V
Biotechnol Bioeng; 2021 Sep; 118(9):3533-3544. PubMed ID: 33914903
[TBL] [Abstract][Full Text] [Related]
29. Enhancing protein A productivity and resin utilization within integrated or intensified processes.
Brinkmann A; Elouafiq S
Biotechnol Bioeng; 2021 Sep; 118(9):3359-3366. PubMed ID: 33638385
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of several protein a resins for application to multicolumn chromatography for the rapid purification of fed-batch bioreactors.
Hilbold NJ; Le Saoût X; Valery E; Muhr L; Souquet J; Lamproye A; Broly H
Biotechnol Prog; 2017 Jul; 33(4):941-953. PubMed ID: 28371561
[TBL] [Abstract][Full Text] [Related]
31. Improving an intensified and integrated continuous bioprocess platform for biologics manufacturing.
Zhou H; Fang M; Zheng X; Zhou W
Biotechnol Bioeng; 2021 Sep; 118(9):3618-3623. PubMed ID: 33788278
[TBL] [Abstract][Full Text] [Related]
32. Continuous capture scale down model: A comparison of a continuous and a discrete approach.
Seidel JC; Göbel M; Dos Reis Rodrigues RC; Kaup NM; Rapp J; Frauenschuh A; Shultz J; Cui H
Biotechnol Bioeng; 2021 Sep; 118(9):3375-3381. PubMed ID: 33638417
[TBL] [Abstract][Full Text] [Related]
33. Single pass tangential flow filtration to debottleneck downstream processing for therapeutic antibody production.
Dizon-Maspat J; Bourret J; D'Agostini A; Li F
Biotechnol Bioeng; 2012 Apr; 109(4):962-70. PubMed ID: 22094920
[TBL] [Abstract][Full Text] [Related]
34. Integrated continuous biomanufacturing platform with ATF perfusion and one column chromatography operation for optimum resin utilization and productivity.
Kamga MH; Cattaneo M; Yoon S
Prep Biochem Biotechnol; 2018 May; 48(5):383-390. PubMed ID: 29509101
[TBL] [Abstract][Full Text] [Related]
35. White paper on continuous bioprocessing. May 20-21, 2014 Continuous Manufacturing Symposium.
Konstantinov KB; Cooney CL
J Pharm Sci; 2015 Mar; 104(3):813-20. PubMed ID: 25417595
[TBL] [Abstract][Full Text] [Related]
36. Enablers of continuous processing of biotherapeutic products.
Rathore AS; Zydney AL; Anupa A; Nikita S; Gangwar N
Trends Biotechnol; 2022 Jul; 40(7):804-815. PubMed ID: 35034769
[TBL] [Abstract][Full Text] [Related]
37. Fed-batch and perfusion culture processes: economic, environmental, and operational feasibility under uncertainty.
Pollock J; Ho SV; Farid SS
Biotechnol Bioeng; 2013 Jan; 110(1):206-19. PubMed ID: 22806692
[TBL] [Abstract][Full Text] [Related]
38. Gamma irradiating chromatography columns enables bioburden-free integrated continuous biomanufacturing.
Varner C; Patil R; Godawat R; Warikoo V; Konstantinov K; Brower KP
Biotechnol J; 2021 Apr; 16(4):e2000298. PubMed ID: 33314754
[TBL] [Abstract][Full Text] [Related]
39. A new large-scale manufacturing platform for complex biopharmaceuticals.
Vogel JH; Nguyen H; Giovannini R; Ignowski J; Garger S; Salgotra A; Tom J
Biotechnol Bioeng; 2012 Dec; 109(12):3049-58. PubMed ID: 22688835
[TBL] [Abstract][Full Text] [Related]
40. Engineering death resistance in CHO cells for improved perfusion culture.
MacDonald MA; Nöbel M; Martínez VS; Baker K; Shave E; Gray PP; Mahler S; Munro T; Nielsen LK; Marcellin E
MAbs; 2022; 14(1):2083465. PubMed ID: 35737825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
